Literature DB >> 35043006

T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant.

Seong Jin Choi1, Dong-Uk Kim2, Ji Yun Noh2,3, Sangwoo Kim4, Su-Hyung Park2, Hye Won Jeong2,5, Eui-Cheol Shin6,7.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35043006      PMCID: PMC8764507          DOI: 10.1038/s41423-022-00838-5

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


× No keyword cloud information.
In November 2021, the Omicron variant (B.1.1.529) emerged and was designated a variant of concern (VOC) by the World Health Organization. Recently, Omicron was reported to extensively escape neutralizing antibodies elicited by COVID-19 vaccination or natural infection [1-3]. However, whether Omicron evades the T cell immunity elicited by COVID-19 vaccination or natural infection remains to be elucidated. To address this issue, we analyzed the amino acid sequences of T cell epitopes identified from the original SARS-CoV-2 strain (Wuhan-Hu-1) in the Omicron variant (hCoV-19/South Africa/CERI-KRISP-K032284/2021). First, we examined 454 major histocompatibility complex (MHC) class I-restricted CD8+ T cell epitopes that were previously identified by activation-induced marker (AIM) assays [4]. In the Omicron variant, 88.4% (137/155) of epitopes from the spike protein and 98.3% (294/299) of epitopes from nonspike proteins were fully conserved (Fig. 1A), and 94.9% (431/454) of CD8+ T cell epitopes were completely conserved. We performed a similar analysis with 122 CD8+ T cell epitopes that were previously identified by a systematic analysis using peptide-MHC class I complex multimers [5]. In the Omicron variant, 88.9% (16/18) and 98.1% (102/104) of epitopes from the spike and nonspike proteins, respectively, were fully conserved, and 96.7% (118/122) of CD8+ T cell epitopes were completely conserved. We identified 19 dominant epitopes by a meta-analysis of CD8+ T cell epitope data from 18 studies with 852 COVID-19 convalescents [6], and all 19 CD8+ T cell epitopes were completely conserved in the Omicron variant. We also examined 280 MHC class II-restricted CD4+ T cell epitopes that were previously identified by AIM assays [4]. In the Omicron variant, 80.4% (74/92) and 94.7% (178/188) of epitopes from the spike and nonspike proteins, respectively, were fully conserved, and 90.0% (252/280) of CD4+ T cell epitopes were completely conserved. These results indicate that the majority of T cell epitopes are considerably conserved in the Omicron variant.
Fig. 1

T cell analysis against the Omicron variant. A Amino acid sequences of T cell epitopes identified from the original SARS-CoV-2 strain (NC_045512.2) were examined in the Omicron variant (EPI_ISL_6699770, GISAID). Four different sets of previously identified T cell epitopes were used for comparisons. Percentages of completely conserved epitopes are presented as bar graphs. B, C IFN-γ intracellular staining was performed using PBMCs from COVID-19 convalescents (N = 7; 45–125 days after symptom onset) and BNT162b2-vaccinated individuals (N = 12; 3 months after the second vaccination). PBMCs were stimulated with OLP pools to spike the original strain and Omicron. The ratio of the frequency of IFN-γ+ cells after stimulation with the Omicron spike OLPs to the frequency after stimulation with the original spike OLPs is presented as a percentage. Statistical analysis was performed using paired t tests. *p < 0.05; ns not significant

T cell analysis against the Omicron variant. A Amino acid sequences of T cell epitopes identified from the original SARS-CoV-2 strain (NC_045512.2) were examined in the Omicron variant (EPI_ISL_6699770, GISAID). Four different sets of previously identified T cell epitopes were used for comparisons. Percentages of completely conserved epitopes are presented as bar graphs. B, C IFN-γ intracellular staining was performed using PBMCs from COVID-19 convalescents (N = 7; 45–125 days after symptom onset) and BNT162b2-vaccinated individuals (N = 12; 3 months after the second vaccination). PBMCs were stimulated with OLP pools to spike the original strain and Omicron. The ratio of the frequency of IFN-γ+ cells after stimulation with the Omicron spike OLPs to the frequency after stimulation with the original spike OLPs is presented as a percentage. Statistical analysis was performed using paired t tests. *p < 0.05; ns not significant Next, we performed IFN-γ intracellular cytokine staining (ICS) assays by stimulating peripheral blood mononuclear cells (PBMCs) using overlapping peptide (OLP) pools for the spike protein of the original SARS-CoV-2 strain and Omicron. PBMCs were obtained from individuals who had recovered from infection with the original SARS-CoV-2 and individuals vaccinated with BNT162b2. Among convalescent individuals, the frequency of IFN-γ+ cells after stimulation with the Omicron spike OLPs was 76.74% and 88.03% of the frequency after stimulation with the original spike OLPs in CD8+ and CD4+ T cells, respectively, without significant differences (Fig. 1B). Among vaccinated individuals, the frequency of IFN-γ+ cells after stimulation with the Omicron spike OLPs was 80.42% and 83.90% of the frequency after stimulation with the original spike OLPs in CD8+ and CD4+ T cells, respectively (Fig. 1B). The decrease in the CD8+ T cell response was significant (P = 0.03), but the change in the CD4+ T cell response was not. These results demonstrate that considerable proportions (>75%) of SARS-CoV-2 spike-specific memory CD8+ and CD4+ T cells elicited by COVID-19 vaccination or natural infection recognize and respond to the Omicron spike. Previously known VOCs, including the Beta (B.1.351) and Delta (B.1.617.2) variants, reduce the neutralizing activities of antibodies induced by COVID-19 vaccination or natural infection [7]. However, such VOCs rarely evade memory T cell responses elicited by COVID-19 vaccination or natural infection [8]. In principle, VOCs can hardly evade T cell responses because multiple T cell epitopes are scattered across structural and nonstructural proteins. COVID-19 vaccination or natural infection induces not only neutralizing antibodies but also memory T cells. Virus-specific CD8+ and CD4+ T cells exert antiviral functions by eliminating virus-infected cells and producing effector cytokines, leading to rapid control of viral infection and reducing disease severity [9]. Although the Omicron variant escapes neutralizing antibodies induced by COVID-19 vaccination or natural infection [1-3], our current analysis demonstrates that T cell epitopes are considerably conserved in the Omicron variant and that substantial proportions of memory T cells elicited by COVID-19 vaccination or natural infection respond to the Omicron spike. These results indicate that memory T cells may provide protective immunity during reinfection or breakthrough infection with the Omicron variant. Methods and materials
  6 in total

1.  Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.

Authors:  Timothée Bruel; Etienne Simon-Lorière; Felix A Rey; Olivier Schwartz; Delphine Planas; David Veyer; Artem Baidaliuk; Isabelle Staropoli; Florence Guivel-Benhassine; Maaran Michael Rajah; Cyril Planchais; Françoise Porrot; Nicolas Robillard; Julien Puech; Matthieu Prot; Floriane Gallais; Pierre Gantner; Aurélie Velay; Julien Le Guen; Najiby Kassis-Chikhani; Dhiaeddine Edriss; Laurent Belec; Aymeric Seve; Laura Courtellemont; Hélène Péré; Laurent Hocqueloux; Samira Fafi-Kremer; Thierry Prazuck; Hugo Mouquet
Journal:  Nature       Date:  2021-07-08       Impact factor: 49.962

2.  SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8+ T cell activation in COVID-19 patients.

Authors:  Ditte Stampe Hersby; Tripti Tamhane; Sunil Kumar Saini; Helle Rus Povlsen; Susana Patricia Amaya Hernandez; Morten Nielsen; Anne Ortved Gang; Sine Reker Hadrup
Journal:  Sci Immunol       Date:  2021-04-14

3.  Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases.

Authors:  Alison Tarke; John Sidney; Conner K Kidd; Jennifer M Dan; Sydney I Ramirez; Esther Dawen Yu; Jose Mateus; Ricardo da Silva Antunes; Erin Moore; Paul Rubiro; Nils Methot; Elizabeth Phillips; Simon Mallal; April Frazier; Stephen A Rawlings; Jason A Greenbaum; Bjoern Peters; Davey M Smith; Shane Crotty; Daniela Weiskopf; Alba Grifoni; Alessandro Sette
Journal:  Cell Rep Med       Date:  2021-01-26

4.  Landscape of epitopes targeted by T cells in 852 individuals recovered from COVID-19: Meta-analysis, immunoprevalence, and web platform.

Authors:  Ahmed Abdul Quadeer; Syed Faraz Ahmed; Matthew R McKay
Journal:  Cell Rep Med       Date:  2021-05-21

5.  Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals.

Authors:  Alison Tarke; John Sidney; Nils Methot; Esther Dawen Yu; Yun Zhang; Jennifer M Dan; Benjamin Goodwin; Paul Rubiro; Aaron Sutherland; Eric Wang; April Frazier; Sydney I Ramirez; Stephen A Rawlings; Davey M Smith; Ricardo da Silva Antunes; Bjoern Peters; Richard H Scheuermann; Daniela Weiskopf; Shane Crotty; Alba Grifoni; Alessandro Sette
Journal:  Cell Rep Med       Date:  2021-07-02
  6 in total
  22 in total

1.  Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection.

Authors:  Hye Won Jeong; Se-Mi Kim; Min Kyung Jung; Ji Yun Noh; Ji-Seung Yoo; Eun-Ha Kim; Young-Il Kim; Kwangmin Yu; Seung-Gyu Jang; Juryeon Gil; Mark Anthony Casel; Rollon Rare; Jeong Ho Choi; Hee-Sung Kim; Jun Hyoung Kim; Jihye Um; Chaeyoon Kim; Yeonjae Kim; Bum Sik Chin; Sungmin Jung; Jun Yong Choi; Kyoung-Ho Song; Yong-Dae Kim; Jun-Sun Park; Joon Young Song; Eui-Cheol Shin; Young Ki Choi
Journal:  Cell Rep Med       Date:  2022-09-19

Review 2.  SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance.

Authors:  Yifei Guo; Jiajia Han; Yao Zhang; Jingjing He; Weien Yu; Xueyun Zhang; Jingwen Wu; Shenyan Zhang; Yide Kong; Yue Guo; Yanxue Lin; Jiming Zhang
Journal:  Front Immunol       Date:  2022-04-29       Impact factor: 8.786

3.  Omicron's lasting mysteries: four questions scientists are racing to answer.

Authors:  Amber Dance
Journal:  Nature       Date:  2022-03       Impact factor: 69.504

Review 4.  Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic.

Authors:  Rekha Khandia; Shailja Singhal; Taha Alqahtani; Mohammad Amjad Kamal; Nahed A El-Shall; Firzan Nainu; Perumal Arumugam Desingu; Kuldeep Dhama
Journal:  Environ Res       Date:  2022-01-29       Impact factor: 8.431

5.  Cellular therapies for the treatment and prevention of SARS-CoV-2 infection.

Authors:  Susan R Conway; Michael D Keller; Catherine M Bollard
Journal:  Blood       Date:  2022-07-21       Impact factor: 25.476

6.  A SARS-CoV-2 antibody retains potent neutralization against Omicron by targeting conserved RBM residues.

Authors:  Chunyan Yi; Zhiyang Ling; Xiao Lu; Yadong Fu; Zhuo Yang; Sonam Wangmo; Shuangfeng Chen; Yaguang Zhang; Liyan Ma; Wangpeng Gu; Hongzhou Lu; Xiaoyu Sun; Bing Sun
Journal:  Cell Mol Immunol       Date:  2022-03-29       Impact factor: 22.096

Review 7.  Mechanistic Insights Into the Immune Pathophysiology of COVID-19; An In-Depth Review.

Authors:  Areez Shafqat; Shameel Shafqat; Sulaiman Al Salameh; Junaid Kashir; Khaled Alkattan; Ahmed Yaqinuddin
Journal:  Front Immunol       Date:  2022-03-24       Impact factor: 7.561

8.  mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.

Authors:  Matthew Gagne; Juan I Moliva; Kathryn E Foulds; Shayne F Andrew; Barbara J Flynn; Anne P Werner; Danielle A Wagner; I-Ting Teng; Bob C Lin; Christopher Moore; Nazaire Jean-Baptiste; Robin Carroll; Stephanie L Foster; Mit Patel; Madison Ellis; Venkata-Viswanadh Edara; Nahara Vargas Maldonado; Mahnaz Minai; Lauren McCormick; Christopher Cole Honeycutt; Bianca M Nagata; Kevin W Bock; Caitlyn N M Dulan; Jamilet Cordon; Dillon R Flebbe; John-Paul M Todd; Elizabeth McCarthy; Laurent Pessaint; Alex Van Ry; Brandon Narvaez; Daniel Valentin; Anthony Cook; Alan Dodson; Katelyn Steingrebe; Saule T Nurmukhambetova; Sucheta Godbole; Amy R Henry; Farida Laboune; Jesmine Roberts-Torres; Cynthia G Lorang; Shivani Amin; Jessica Trost; Mursal Naisan; Manjula Basappa; Jacquelyn Willis; Lingshu Wang; Wei Shi; Nicole A Doria-Rose; Yi Zhang; Eun Sung Yang; Kwanyee Leung; Sijy O'Dell; Stephen D Schmidt; Adam S Olia; Cuiping Liu; Darcy R Harris; Gwo-Yu Chuang; Guillaume Stewart-Jones; Isabella Renzi; Yen-Ting Lai; Agata Malinowski; Kai Wu; John R Mascola; Andrea Carfi; Peter D Kwong; Darin K Edwards; Mark G Lewis; Hanne Andersen; Kizzmekia S Corbett; Martha C Nason; Adrian B McDermott; Mehul S Suthar; Ian N Moore; Mario Roederer; Nancy J Sullivan; Daniel C Douek; Robert A Seder
Journal:  Cell       Date:  2022-03-25       Impact factor: 66.850

9.  Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

Authors:  Xinxue Liu; Alasdair P S Munro; Shuo Feng; Leila Janani; Parvinder K Aley; Gavin Babbage; David Baxter; Marcin Bula; Katrina Cathie; Krishna Chatterjee; Wanwisa Dejnirattisai; Kate Dodd; Yvanne Enever; Ehsaan Qureshi; Anna L Goodman; Christopher A Green; Linda Harndahl; John Haughney; Alexander Hicks; Agatha A van der Klaauw; Jonathan Kwok; Vincenzo Libri; Martin J Llewelyn; Alastair C McGregor; Angela M Minassian; Patrick Moore; Mehmood Mughal; Yama F Mujadidi; Kyra Holliday; Orod Osanlou; Rostam Osanlou; Daniel R Owens; Mihaela Pacurar; Adrian Palfreeman; Daniel Pan; Tommy Rampling; Karen Regan; Stephen Saich; Teona Serafimova; Dinesh Saralaya; Gavin R Screaton; Sunil Sharma; Ray Sheridan; Ann Sturdy; Piyada Supasa; Emma C Thomson; Shirley Todd; Chris Twelves; Robert C Read; Sue Charlton; Bassam Hallis; Mary Ramsay; Nick Andrews; Teresa Lambe; Jonathan S Nguyen-Van-Tam; Victoria Cornelius; Matthew D Snape; Saul N Faust
Journal:  J Infect       Date:  2022-04-09       Impact factor: 38.637

Review 10.  COVID-19: Omicron - the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2.

Authors:  Harald Brüssow
Journal:  Microb Biotechnol       Date:  2022-04-20       Impact factor: 6.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.